Trial intelligence / Profile preview

Hormonal therapy with or without docetaxel for high-volume metastatic hormone-sensitive prostate cancer

ChiCTR-IPR-15005994Phase 3Recruiting

Sponsor: Fudan University Shanghai Cancer Center
Start: Jan 2015
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Overall survival. Started Jan 2015; status: recruiting.

Drugs

docetaxel

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on ChiCTR-IPR-15005994.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-IPR-15005994.